• BRILINTA 90mg use in Acute Coronary Syndrome

BRILINTA (ticagrelor) 90mg treatment should be initiated with a single 180mg loading dose and then continued at 90mg twice daily. Treatment with BRILINTA (ticagrelor) 90mg twice daily is recommended for 12 months in ACS patients unless discontinuation is clinically indicated. BRILITA (ticagrelor) 90mg can be used in a wide range of ACS patients 

• BRILINTA 90mg can be used in wide range of ACS patients
  

BRILLINTA (ticagrelor) 90mg twice daily, co-administered with aspirin, is indicated for the prevention of atherothrombotic events in adult patients with ACS (unstable angina [UA], non ST-segment-elevated MI [NSTEMI] or ST-segment-elevation MI [STEMI]), including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), for up to 12 months unless discontinuation is clinically indicated.^1,6

• BRILINTA (ticagrelor) 90mg loading and maintenance dose 

Treatment with BRILINTA (ticagrelor) should be initiated with a single 180mg loading dose (two tablets of 90mg) and then continued at 90mg twice daily with concomitant ASA.¹

• No dose adjustment is required across ACS patient populations including:¹
  • Elderly(≥75 years)
  • Renal impairment (not recommended in renal dialysis)
  • Mild hepatic impairment
  • Switching from clopidogrel to BRILINTA (ticagrelor) 90mg

Patients can be switched from clopidogrel to BRILINTA(ticagrelor) 90mg twice daily without interruption of antiplatelet effect1. In the acute phase international guidelines e.g. ESC¹³, endorse giving a loading dose of ticagrelor (180 mg)before commencing the maintenance dose of 90 mg twice daily as usual.